Pectoral Nerve Block Versus Serratus Posterior Superior Intercostal Plane Block for Pain Control After Mastectomy
NCT07929090, Not applicable, Recruiting, Bursa City Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Pectoral Nerve Block Versus Serratus Posterior Superior Intercostal Plane Block for Pain Control After Mastectomy | ClinicalTrials.gov |
| NCT number | NCT07929090 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 78 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Bursa City Hospital | ClinicalTrials.gov |
| Conditions | Postoperative Pain, Breast Cancer, Persistent Postsurgical Pain | ClinicalTrials.gov |
| Interventions | Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block, Ultrasound-Guided Pectoral Nerve Block Type II | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Postoperative Opioid Consumption | First 24 hours postoperatively, with recordings at 0, 2, 4, 8, 16, and 24 hours. | Postoperative opioid consumption will be compared between the groups. Tramadol consumption administered through intravenous patient-controlled analgesia will be recorded in milligrams at 0, 2, 4, 8, 16, and 24 hours postoperatively. The total dose of rescue meperidine will be recorded separately. | ClinicalTrials.gov |
| Secondary | Pain Intensity at Rest | At 0, 2, 4, 8, 16, and 24 hours postoperatively. | Pain intensity at rest will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. | ClinicalTrials.gov |
| Secondary | Pain Intensity During Movement | At 0, 2, 4, 8, 16, and 24 hours postoperatively. | Pain intensity during movement will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. | ClinicalTrials.gov |
| Secondary | Total Rescue Analgesic Dose | During the first 24 hours postoperatively. | The total dose of intravenous meperidine administered as rescue analgesia will be recorded in milligrams. Meperidine at 0.5 mg/kg will be administered when the Numeric Rating Scale score is 4 or higher. | ClinicalTrials.gov |
| Secondary | Time to First Rescue Analgesia | During the first 24 hours postoperatively. | The time of the first postoperative administration of rescue analgesia will be recorded. Intravenous meperidine at 0.5 mg/kg will be administered when the Numeric Rating Scale score is 4 or higher. | ClinicalTrials.gov |
| Secondary | Quality of Recovery-15 Score | At 24 hours postoperatively. | Quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. | ClinicalTrials.gov |
| Secondary | Postoperative Nausea and Vomiting | During the first 24 hours postoperatively. | Postoperative nausea and vomiting will be assessed using a four-category scale: 1 = no nausea or vomiting; 2 = nausea without vomiting; 3 = one episode of vomiting or persistent nausea; and 4 = two or more episodes of vomiting or severe/persistent retching. Higher scores indicate more severe symptoms. | ClinicalTrials.gov |
| Secondary | Persistent Postoperative Pain Assessed Using the McGill Pain Questionnaire | At 3 months postoperatively. | Persistent postoperative pain will be assessed using the McGill Pain Questionnaire during a telephone interview at 3 months after surgery. Participants will provide prior consent for telephone follow-up. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)